Japanese
English
- 有料閲覧
- Abstract 文献概要
- 1ページ目 Look Inside
- 参考文献 Reference
- サイト内被引用 Cited by
要旨 大腸pSM癌の長期成績(多施設共同・遡及的検討)から大腸癌治療ガイドラインの妥当性を検討した.大腸pSM癌626例のうち経過観察可能症例は105例で,長期成績は再発2例(1.9%),死亡3例(原病死1例),5年無再発生存98%,5年全生存93%であった.追加治療が考慮された症例のうち,追加治療非施行群84例と施行群159例において,再発率はそれぞれ7.1%vs. 2.5%,5年無再発生存90% vs. 97%と,統計学的有意差はないものの追加治療施行群に良好な傾向にあり,追加手術の意義が示唆された.長期成績の観点からは,ガイドラインに即した治療法選択は妥当であると考えられたが,実臨床においては,経過観察可能群においても再発の危険性を念頭に置く必要性がある.
We evaluated the Japanese guidelines for SM-CRC(submucosal invasive colorectal cancer)retrospectively from long-term outcomes of SM-CRC. A total of 626 patients with SM-CRC were involved in this study. Of 626 patients, 105 patients were treated by ER(endoscopic resection)alone with low risk of pathological features for lymph-node metastasis. The clinical outcomes were 1.9%(2/105)in recurrence rate, 98% in relapse-free interval, and 93% in overall survival. Regarding recurrence, while there were not significant numbers, patients with high risk treated by ER alone tended to be more numerous than those treated by ER and additional surgery. From this study, In SM-CRC patients with four low risk pathological factors, long-term outcomes of endoscopic resection alone were sufficiently good. In those with high risk pathological features, subsequent surgery could be recommended because of the higher recurrence rate after endoscopic resection alone.
Copyright © 2011, Igaku-Shoin Ltd. All rights reserved.